Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 498-502

  Yan, Jun ^a   Wang, Qianliang ^a   Zou, Kang ^a   Wang, Li ^a   Schwartz, Eric B ^b   Fuchs, James R ^b   Zheng, Zugen ^a   Wu, Jianqiang ^c  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Osteosarcoma; Protein kinase inhibitor; Signal transducers and activators of transcription 3 transcription factor; Xenograft

Indexed keywords

ENZYME INHIBITOR; FLLL32 ENZYME INHIBITOR; JANUS KINASE 2; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; CURCUMIN; FLLL 32; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; THERAPY EFFECT; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; BONE NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOLOGY; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; MICE; OSTEOSARCOMA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926643036     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3439     Document Type: Article

References (24)

1. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop Surg 17: 515-527, 2009.
2. Jaffe N: Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 152: 239-262, 2009.
3. Federman N, Bernthal N, Eilber FC and Tap WD: The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 10: 82-93, 2009.
4. Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11: 670-678, 2010.
5. Scotlandi K, Picci P and Kovar H: Targeted therapies in bone sarcomas. Curr Cancer Drug Targets 9: 843-853, 2009.
6. O'Day K and Gorlick R: Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 9: 511-523, 2009.
7. Whelan J, Patterson D, Perisoglou M, et al: The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 54: 350-354, 2010.
8. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
9. Murase M, Kano M, Tsukahara T, et al: Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 101: 1425-1432, 2009.
10. Takeda K, Noguchi K, Shi W, et al: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94: 3801-3804, 1997.
11. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98: 295-303, 1999.
12. Wang YC, Zheng LH, Ma BA, et al: Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem 113: 402-408, 2011.
13. Fossey SL, Liao AT, McCleese JK, et al: Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 9: 81, 2009.
14. Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976, 2005.
15. Wang YC, Zheng LH, Ma BA, et al: Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem 113: 402-408, 2011.
16. Ryu K, Choy E, Yang C, et al: Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res 28: 971-978, 2010.
17. Lin L, Hutzen B, Zuo M, et al: Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70: 2445-2454, 2010.
18. Miller SJ, Rangwala F, Williams J, et al: Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 66: 2584-2591, 2006.
19. Wang X, Goldstein D, Crowe PJ and Yang JL: Impact of STAT3 inhibition on survival of osteosarcoma cell lines. Anticancer Res 34: 6537-6545, 2014.
20. Tian J, Li X, Si M, Liu T and Li J: CD271+ osteosarcoma cells display stem-like properties. PLoS One 9: e98549, 2014.
21. Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng 23: 17-34, 2006.
22. Hokaiwado N, Takeshita F, Banas A and Ochiya T: RNAi-based drug discovery and its application to therapeutics. IDrugs 11: 274-278, 2008.
23. Krishnamachary B, Glunde K, Wildes F, et al: Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res 69: 3464-3471, 2009.
24. Li J, Piao YF, Jiang Z, et al: Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J Gastroenterol 15: 2602-2608, 2009.